Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 21, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,450,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,441.5 pence per share; lowest price paid was 1,429 pence per share.
- Treasury Holdings (Settled): 492,665,427 shares (9.05% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,015,427 shares (10.04% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,950,843,777 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,450,000 shares on September 21, 2012. This transaction increased the proportion of shares held in Treasury to 10.04% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (492,665,427 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding treasury shares (4,950,843,777) for voting rights calculations.
- Check the settlement status of the 4,350,000 shares included in the "including shares which have been purchased but not yet settled" figure to reconcile the difference between settled and total treasury holdings.